Neu-Sensamide radiation sensitizer: OXGN amended its Phase III clinical trial

The Phase III protocol for Neu-Sensamide will now target squamous cell carcinoma, and will continue to enroll patients only in Europe, where standard therapy is more likely to rely on radiation alone. OXGN expanded the enrollment in Europe from 220 to 350 patients.

The trial will stop enrolling patients in the U.S. where standard therapy combines radiation and chemotherapy, rather than radiation alone. In the U.S., OXGN will focus on two ongoing Phase II studies in patients with any type of non-small cell lung cancer, who are treated with radiation, chemotherapy and Neu-Sensamide. ...